SLN
Silence Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Consensus Rating "Strong Buy"
MACD Golden Cross
Ample Liquidity
High Gross Profit Margin
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SLN
Silence Therapeutics Plc
A leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases
Biological Technology
11/18/1994
09/08/2020
NASDAQ Stock Exchange
116
12-31
Depository Receipts (Ordinary Shares)
72 Hammersmith Road, London, W14 8TH United Kingdom
--
Silence Therapeutics Plc was incorporated on 18 November 1994 as a public limited company under the laws of England and Wales. The company is a biotechnology company focused on the discovery and development of new molecules, including short interfering ribonucleic acid (siRNA), to inhibit the expression of specific target genes that are thought to play a role in the pathological processes of diseases with significant unmet medical needs.
Company Financials
EPS
SLN has released its 2025 Q3 earnings. EPS was reported at -0.15, versus the expected -0.21, beating expectations. The chart below visualizes how SLN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SLN has released its 2025 Q3 earnings report, with revenue of 159.00K, reflecting a YoY change of -89.39%, and net profit of -20.96M, showing a YoY change of 41.04%. The Sankey diagram below clearly presents SLN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
